Aptus Capital Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-68,299
Closed -$2.54M 503
2019
Q4
$2.54M Buy
68,299
+12,332
+22% +$439K 0.18% 116
2019
Q3
$1.91M Buy
+55,967
New +$2.04M 0.11% 131

Other funds holding PFE

Aptus Capital Advisors's PFE Position: Q1 2026 in Review

Aptus Capital Advisors increased its Pfizer (PFE) stake by 136% in Q1 2026, buying an estimated $5.5M and bringing the position to 358,846 shares worth $10.1M. The position accounts for 0.08% of the portfolio, ranked #212.

Aptus Capital Advisors first reported a position in PFE in Q4 2018 and has held it in 30 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Aptus Capital Advisors held 358,846 shares of Pfizer worth $10.1M as of Q1 2026.
  • Aptus Capital Advisors bought 206,642 Pfizer shares in Q1 2026, an estimated $5.5M.
  • Pfizer made up 0.08% of Aptus Capital Advisors's portfolio in Q1 2026, its #212 holding.
  • Aptus Capital Advisors first reported a position in Pfizer in Q4 2018 and has held it in 30 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.